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Abstract
The internal tandem duplication (ITD) of the juxtamembrane region of the FLT3 receptor has been associated with increased
reactive oxygen species (ROS) generation in acute myeloid leukemia (AML). How this elevated level of ROS contributes to
the leukemic phenotype, however, remains poorly understood. In this work we show that ROS in the FLT3-ITD expressing
AML cell line MV4-11 is reduced by treatment with PKC412, an inhibitor of FLT3, DPI, a flavoprotein inhibitor, and VAS2870,
a Nox specific inhibitor, suggesting that ROS production is both FLT3 and NADPH oxidase dependent. The majority of these
ROS co-localize to the endoplasmic reticulum (ER), as determined with the H2O2-specific aryl-boronate dye Peroxyorange 1,
which also corresponds to co-localization of p22phox. Moreover, knocking down p22phox dramatically reduces H2O2 after
24 hours in the ER, without affecting mitochondrial ROS. Significantly, the FLT3 inhibitor PKC412 reduces H2O2 in FLT3-ITD
expressing cell lines (MV4-11, MOLM-13) through reduction of p22phox over 24 hours. Reduced p22phox is achieved by
proteasomal degradation and is prevented upon GSK3-b inhibition. Knockdown of p22phox resulted in reduced STAT5
signalling and reduced Pim-1 levels in the cells after 24 hours. Thus, we have shown that FLT3 driven H2O2 production in
AML cells is mediated by p22phox and is critical for STAT5 signalling.
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Introduction
Aberrant signalling through receptor tyrosine kinases (RTKs) is
known to be a significant pathway in tumour development and
perpetuation [1]. FMS-like tyrosine kinase 3 (FLT3) is a type III
RTK expressed in approximately 90% of acute myeloid leukemia
(AML) and activating mutations of FLT3 are found in approx-
imately 30% of all AML cases [2]. In fact, FLT3 is the most
frequently mutated gene associated with AML [3]. The most
prevalent mutation of FLT3 is the internal tandem duplication
(ITD) of the juxtamembrane domain conferring constitutive
activation of the tyrosine kinase domain, leading to autophospho-
rylation of the receptor and subsequent phosphorylation of
substrate proteins [2]. Moreover, several studies have demonstrat-
ed that the prognosis for AML patients with FLT3-ITD is
relatively poor [4]. Also of significant clinical relevance is the
association of FLT3-ITD with increased chemoresistance in AML
patients [5]. Constitutive activation of FLT3 switches on
downstream signalling pathways such as PI3K/Akt, Ras/Raf/
MAPK and Jak/STAT [6]. Activation of these pathways in
myeloid cells is known to promote survival, proliferation, and
transformation [7,8,9]. Interestingly, FLT3-ITD expressing cell
lines are known to have increased levels of endogenous reactive
oxygen species (ROS) [10], although it is still unclear precisely
what advantage this confers on the cells.
ROS were traditionally thought of as an unwanted by-product
of cellular respiration, but in recent years there has been in a
renaissance of research into their role as mediators of intracellular
signalling [11]. Key to the renewal of interest in the field was that
levels of endogenous ROS in some tumour cells are elevated
[12,13,14]. Major oncogenes such as Bcr/Abl, Ras and c-myc have
all been shown to induce ROS production [15,16]. The increased
level of steady-state ROS has been linked to numerous cellular
processes associated with tumour development such as transfor-
mation, upregulation of pro-survival pathways or DNA-damage
inducing mutations. The imbalance is derived either from an
increase in ROS production or through a decrease in levels of
ROS scavenging proteins [13]. Unravelling the precise mecha-
nisms involved has proven to be difficult and to date we have a
poor understanding of the precise role of ROS in tumours.
Similar to other tumours, increased ROS has been seen in a
number of myeloid diseases. Haematopoietic growth factor
signalling is mediated through ROS [17]. In T-cell acute
lymphoblastic leukemia it has been shown that ROS regulates
Phosphatase and tensin homolog (PTEN) contributing to in-
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creased viability in culture [18]. The development of Fanconi
anemia has also been linked with elevated ROS driving genetic
instability [19]. Work by our group and others demonstrated that
in chronic myeloid leukemia (CML) Bcr-Abl induced ROS
regulates the PI3K/Akt pathway [20,21]. This work by Naughton
et al. demonstrated that the NADPH oxidase Nox4 was respon-
sible for producing ROS upon Bcr-Abl induction which contrib-
uted to survival in a myeloproliferative disorder (20).
Nox proteins were originally identified in phagocytes, where
Nox2 was shown to generate ROS as part of the innate immune
system, but numerous homologues have since been identified
outside of phagocytes [22]. These Nox proteins have been
associated with signal transduction in a number of contexts and
are now also associated with the development of numerous
pathologies [23,24]. Specific spatial and temporal regulation of
Nox activity and/or expression confers a mechanism of controlling
ROS within the cell and downstream pathways [25]. How the cell
achieves this is not understood in much detail. In recent years a
number of Nox regulator proteins have been uncovered but no
clear overarching mechanism of regulation has been determined.
Nox-derived ROS are known to play a role in FLT3-ITD AML,
with increased production associated with the mutant receptor
[10]. Sallmyr et al. also showed that this was associated with
increased binding of Rac1 to Nox2, suggesting that Nox2 was at
least partly involved.
In this study we used a number of leukemic cell lines, expressing
wild-type and mutated FLT3, to investigate elevated endogenous-
ROS associated with FLT3-ITD. We show that the vast majority
of H2O2 in these cells localize to the enodoplasmic reticulum (ER).
Inhibition of FLT3 signalling by means of PKC412, which is
currently in phase II clinical trials for AML [26], leads to a loss in
this ER localized ROS concomitantly with the post-translational
downregulation of the small membrane-bound component of the
Nox complex, p22phox. Thus, we propose that increased H2O2
signalling via FLT3 in AML cell lines is derived from the ER via
p22phox and that treatment of cells with PKC412 drives down
ROS through regulation of p22phox.
Materials and Methods
Cell lines, culture conditions and treatment
The human leukemic cell lines MV4-11 and MOLM-13,
(homozygous and heterozygous for the FLT3-ITD mutation,
respectively) as well as HL-60, were maintained in RPMI 1640
medium supplemented with 10% fetal calf serum, 2mM L-
glutamine and 1% penicillin/streptomycin (all from Sigma
Aldrich, Dublin, Ireland) in a humidified incubator at 37uC with
5% CO2. Inhibition of FLT3-ITD signalling was achieved using
PKC412 (250nM; Tocris Biosciences, Bristol, UK) for up to
24 hours. Nox inhibition was via flavoprotein inhibitor dipheny-
leneiodonium (5mM DPI; Sigma) or VAS2870 (10 mM; Enzo Life
Sciences, Exeter, UK) for up to 1 hour. Inhibition of the 20S
proteasome was via lactacystin (5mM; Sigma) for up to 8 hours.
GSK3-b inhibition was via lithium chloride (10mM; Sigma) or SB
216763 (10mM; Tocris) for up to 8 hours.
Measurement of Intracellular ROS by Flow Cytometry
Following treatments, ROS levels were determined using the
cell-permeable fluorogenic probe 2, 7-dichlorodihydrofluorescin
diacetate (DCF, Invitrogen Biosciences, Dun Laoghaire, Ireland).
Briefly, DCF (50mM) was added to cells in suspension 30 min, and
incubated in the dark, before analysis on a FACScalibur (Becton
and Dickinson, Oxford, UK) with excitation and emission spectra
set at 488 and 530 nm, and using CellQuest software. H2O2 and
O2
2 production was calculated by the increase in mean
fluorescence.
Antibodies
Primary antibodies used for immonoblotting or immunoprecip-
itation were Akt (#9272), phospho-Akt (Thr308; #9276S), ERK
(#9102), phospho-ERK (Thr202/204; #9275S), GSK3-b
(#9315), phospho- GSK3-b (Ser9; #9336S), Pim-1 (#2907S; all
from Cell Signalling Technology, Boston, MA, USA), Nox1
(#SC25545), Duox (sc-48858), p22phox (#SC20781; all from
Santa Cruz Biotechnology, Santa Cruz, CA, USA), GAPDH
(#RGM2-500; Advanced Immunochemicals, Long Beach, CA,
USA), b-Actin (#A5441; Sigma), STAT5 (#610191; BD Biosci-
ences, Oxford, UK), phospho-STAT5 (Tyr694/699; #04-886),
ubiquitin (#MAB1510), Nox2 (#07-024; all from Millipore, Cork,
Ireland), KDEL (#ab12223; Abcam, Cambridge, UK). Nox4
antibody was a kind gift from Dr JD Lambeth (Emory University
School of Medicine, Atlanta, GA, USA). Nox5 antibody was a
kind gift from Dr WM Nauseef (Department of Medicine,
University of Iowa and the Veterans’ Administration Medical
Center, Iowa City, IA, USA). All secondary antibodies for western
blotting were peroxidase conjugated (Dako, Glostrup, Denmark).
Immunofluorescence and Microscopy
Confocal fluorescence live imaging studies were performed with
a Zeiss LSM510 META confocal microscope fitted with a 6361.4
plan apochromat lens. Excitation of PO1 at 543nm was carried
out with Ar laser and emission was collected between 560–615nm.
Excitation of MitoPY11 at 514nm was carried out using Ar laser
and collected between 505–550nm. Excitation of ER tracker blue
at 405nm was carried out using HeNe laser and emission was
collected between 420–480nm. Excitation of ER tracker green at
488nm was carried out using Ar laser and emission was collected
between 505–530nm. The multi-tracking mode of scanning was
applied for acquisition of the images. Image analysis was
performed in MetaMorph Offline and Carl Zeiss Zen 2009 Light
Edition.
Aprroximately 4–5 hours (for PKC412 and VAS-2870 treat-
ments) or 24 hrs (after siRNA transfection) before imaging MV-
411 cells were plated on poly-D-lysine (#P4707; Sigma) coated
glass bottomed dishes (#P35G-1.5-14-C; MatTek Corporation,
Ashland,). 1hr before imaging, ER tracker dye (1mM; Molecular
probes), Peroxy Orange (PO1; 15mM), Mito PY1 (8mM) were
added. Where indicated, cells were treated with PKC412 (200nM)
or VAS-2870 (10mM) for 1hr before imaging. After treatment, cells
were washed twice with PBS buffer and incubated in fresh
medium during imaging.
Briefly, for siRNA experiments MV4-11 cells were cultured for
24 hours before the experiment in Poly-D-lysine coated glass
bottomed dishes and imaged as previously described [27]. For
localization studies of p22phox, MV4-11 cells were cultured for 16
hours on Poly-D-lysine coverslips then fixed for 1hr in 3% PFA/
PBS. The cells were then permeabilised using 0.05% saponin/
0.2% BSA/PBS for 5 min. The coverslips were incubated with
50ml of KDEL and p22phox primary antibody solutions (1/100 in
FBS/PBS) and incubated for 1hr following washing with PBS.
50ml of Alexa fluor 594 and Alexa fluor 488 secondary antibody
solutions (1/200 in FBS/PBS) were added onto coverslips and
incubated for 1hr. The coverslips were washed with PBS and
water and mounted on the slides using moviol. Images were
acquired using multiphoton laser scanning microscope Flou-
view1000 MPE (Mason Technology Dublin, Ireland) with 100x
oil immersion objective. Images are represented as a single slice
from a Z stack projection. The p22phox/Alexa fluor 488 antibody
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Figure 1. Inhibition of FLT3-ITD signalling reduces Nox-derived ROS in the Endoplasmic Reticulum. (a) Flow cytometric analysis of
intracellular ROS as measured by DCF fluorescence in MV4-11, MOLM-13, HL-60 untreated leukemic cell lines (Unt) and following treatment with
PKC412 (250nM) or VAS2870 (10mM) or DPI (5mM) for 1 hours. Mean fluorescence of untreated cells (black lines) is overlaid with that of PKC412 or DPI
treated cells (green lines). Bar chart shows relative mean DCF fluorescence of PKC412, VAS2870 or DPI treated cells as a percentage of control
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was excited using 488nm wavelength and KDEL/Alexa fluor 594
was excited using 543nm wavelength. The sequential scanning
mode was applied for the acquisition of the images. Digital images
were analyzed with Meta-Morph software (Universal Imaging,
West Chester, PA).
Immunoblotting
Cells were lysed with RIPA buffer [Tris–HCl (50mM; pH 7.4),
1% NP-40, 0.25% sodium deoxycholate, NaCl (150mM), EGTA
(1mM), sodium orthovanadate (1mM), sodium fluoride (1mM),
cocktail protease inhibitors (Roche, Welwyn, Hertforshire, UK)
and 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride
(200mM)] for 20 min on ice followed by centrifugation at 14
000 g for 15 min to remove cell debris. Equivalent amounts of
protein, as determined by the Bio-Rad Protein Assay (Bio-Rad,
Hemel Hempstead, UK) were resolved using SDS–polyacrylamide
gel electrophoresis followed by transfer to nitrocellulose membrane
(Schleicher and Schuell, Dassel, Germany) and incubated over-
night with the appropriate antibodies. Membrane development
was achieved using enhanced chemiluminescence (GE Healthcare,
Buckinghamshire, UK).
Immunoprecipitation
Briefly, approximately 16107 cells were lysed, as described
above, and reconstituted at a concentrated of 1mg/mL with RIPA
buffer. Total protein was incubated with anti-p22phox antibody
(1/100 dilution) for 2 hours with rocking at 4uC. 20mL of Protein
A/G PLUS –Agarose (Santa Cruz Biotechnology) was then added
and incubated overnight at 4uC. This solution was then spun down
at maximum speed in a microcentrifuge for 1 minute and the
supernatant was removed. The beads were washed 5 times with
PBS prior to resuspension in loading dye with Dithiothreitol
(DTT; Sigma) and boiling at 90uC for 5 mins. This solution was
then spun down at maximum speed in a microcentrifuge for 1
minute and the total supernatant resolved using SDS–polyacryl-
amide gel electrophoresis, as described above.
Small Interfering RNA (siRNA)
RNA interference mediated by duplexes of 21-nucleotide RNA
was performed in MV4-11 cells. Different Ambion Silencer Select
predesigned siRNA (Applied Biosystems, Warrington, UK) were
used for silencing. For p22phox, the siRNA used were siRNA ID
s3786 and s194371 (Ambion). For the negative control, the siRNA
used were Silencer Select Negative Control #1 siRNA (Ambion).
The sequences are available from the manufacturer website. The
transfection of siRNA used the Amaxa Nucleofactor technology
with the Amaxa cell optimization kit L (Amaxa, Cologne,
Germany) and followed the Amaxa guidelines using program Q-
001.
Quantitative PCR
Quantitative PCR was performed on oligo-dT generated cDNA
using the MJ Research Opticon 2 detection system in combination
with the Quantitect SYBR Green PCR Master Mix (Qiagen,
Crawley, UK). The primers for p22phox and b-Actin were
purchased as Quantitect Primer Assays (Qiagen). The following
PCR parameters were used for each primer set: denaturing at
95uC for 15 min, followed by 45 cycles of 94uC for 15 seconds,
annealing temperature of 56uC for 30 seconds and extension at
72uC for 30 seconds. RNA sample was analyzed in triplicate, and
p22phox expression relative to b-2-microglobulin was obtained by
the equation 2ˆ(Ct-Control)/2ˆ(Ct-Target). Data were represented
as the mean relative expression 6 standard deviation (SD).
Statistical significance was evaluated by Student’s t-test for
comparisons between groups. PCR products were then visualised
by separation on a 2% agarose gel and staining with SYBR Safe
gel stain (Invitrogen).
Statistical analysis
Data are given as mean 6 SD. Statistical significance was
evaluated by Student’s t-test for comparisons between groups, and
analysis of variance (ANOVA).
Results
Inhibition of FLT3-ITD signalling reduces Nox-derived
ROS in the Endoplasmic Reticulum
MV4-11 and MOLM-13 are established IL-3 independent
myelomonocytic leukemia cell lines homozygous and heterozygous
for FLT3-ITD, respectively. Both of these cell lines have been used
as models of FLT3-ITD AML in numerous studies to date and
display a higher endogenous ROS level compared to cells with
non-mutated receptors [10]. The receptor tyrosine kinase inhibitor
PKC412 has been shown to inhibit autophosphorylation of
mutant FLT3 receptors [28] and disrupt downstream signalling
in AML cells [10]. We show that treatment of MV4-11 and
MOLM-13 cells with PKC412 resulted in decreased endogenous
ROS, and this decrease in ROS was not observed when either
HL-60 cells were treated with PKC412 (Figure 1a). The level of
ROS reduction in MOLM-13 and MV4-11 was comparable.
Previous work, by our group and others, has linked Nox proteins
with the production of ROS in leukemic cell lines [10,21,29].
Here, we show that treatment with DPI, a flavoprotein inhibitor,
reduces the ROS in MV4-11 and MOLM -13 cells to a greater
extent than in HL-60 (Figure 1a). This result is confirmed with the
Nox-specific inhibitor VAS2870, which reduced ROS in the
MV4-11 and MOLM -13 to a level comparable with FLT3-
inhibition while no reduction of ROS was seen in HL-60 cells
treated with VAS2870 (Figure 1a). Taken together these results
suggest that Nox proteins are involved in the production of ROS
downstream of FLT3-ITD signalling.
Recently FLT3 was shown to affect signalling outcomes in the
endoplasmic reticulum (ER) [6,30]. To investigate whether the
increased ROS levels in FLT3-ITD cells is associated with this
signalling we examined intracellular Peroxy Orange 1 (PO1)
fluorescence using multi-photon microscopy in MV4–11 cells. We
demonstrate that the highest level of ROS intensity seen with false
colour imaging and the PO1 dye displays a consistent pattern
(Figure 1b). Detection of endogenous H2O2 with PO1 correlates
untreated cells. All results are expressed as mean 6 SD and are representative of three independent experiments. Statistical analysis was performed
using ANOVA (*p,0.005). (b) MV4-11 cells were plated on the poly-D-lysine coated glass bottomed dishes and stained with Peroxyorange 1 (PO1).
Pseudo-coloured image on the left represents intensity distribution (from highest intensity indicated by white to the lowest designated by black) (c)
Cells were incubated with ER tracker, Peroxy Orange and where indicated with PKC412 (250nM;) or (d) VAS-2870 (10mM) for an hour at 37uC/5% CO2
followed by multi-tracking imaging using Zeiss LSM510 META confocal microscope. ER tracker and PO1 probes were excited at 488nm and 543nm
respectively and their emissions were collected at 505–530nm and 560–615nm respectively (e) Cells were incubated with MitoPY1 and where
indicated with PKC412 (250nM) or VAS-2870 (10mM) for an hour at 37uC/5% CO2 followed by imaging using Zeiss LSM510 META confocal microscope.
MitoPY1 was excited at 514nm with a subsequent collection of emission between 505–550nm.
doi:10.1371/journal.pone.0034050.g001
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Figure 2. Inhibition of FLT3-ITD signalling reduces p22phox levels in the Endoplasmic Reticulum. (a) Western blot analysis of Nox
protein expression in untreated MV4-11 cells (Unt), vehicle controls (Veh) and following treatment with PKC412 (250nM) over 24 hours using b-Actin
as loading control. Histograms represent the ratio of the intensity of target bands quantified by densitometry factored by the densitometric
measurement of loading control band. The data are expressed as percentage of control, where the ratio in the control was defined as 1. Values are
the mean 6 SD and are representative of three independent experiments. Western blot analysis of p22phox protein expression: (b) in untreated
MOLM-13 (Unt), vehicle controls (Veh) and following treatment with PKC412 (250nM); (c) in untreated MV4-11(Unt), vehicle controls (Veh) and
following treatment with CEP-701 (50nM); (d) in untreated HL-60 (Unt), vehicle controls (Veh) and following treatment with PKC412 (250nM) over
24 hours using b-Actin as loading control.(e) MV4-11 cells were cultured for 16 hours in Poly-D-lysine coated glass bottomed dishes. Cells were fixed
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well with the ER-tracker dye suggesting an ER source for these
ROS (Figure 1c & d). Importantly H2O2 in the ER was
dramatically reduced by treatment with PKC412 and VAS2870
(Figure 1c & d; Figure S1), demonstrating that they are both
FLT3-ITD and Nox dependent. To test whether treatment of
MV4-11 cells with these inhibitors had any effect on mitochon-
drial sources of ROS we incubated them with the MitoPY1 dye
(Figure 1e; Figure S2) [31]. Inhibiting either FLT3 or Nox
proteins resulted in no reduction in mitchondrial ROS. Thus,
these data demonstrate that FLT3 drives endogenous ROS in the
ER through Nox proteins.
Inhibition of FLT3-ITD signalling reduces p22phox levels
in the Endoplasmic Reticulum
Given that both DPI and PKC412 treatment result in a large
drop in ROS, we investigated whether Nox proteins changed in
expression upon FLT3 inhibition, to determine if this reduction
was mediated through a decrease in Nox protein expression
(Figure 2a). We examined Nox proteins known to be expressed in
leukemic cells [29]. While none of the Nox proteins themselves
show a change in expression, we observed a reduction in the
protein levels of the small membrane component of the Nox
complex, p22phox, in MV4-11 cells (Figure 2a). p22phox was
shown to decrease at 8 hours post PKC412 treatment, and none
remains after 24 hours. A similar decrease at 8 and 24 hours was
observed in the MOLM -13 cell line also (Figure 2b). To ensure
this was a specific effect of the small-molecule inhibitor on FLT3-
ITD signalling we treated the cells with CEP-701, another small
molecule inhibitor of FLT3, and observed the same result
(Figure 2c). Also we have seen that PKC412 had no effect on
ROS or p22phox protein levels in cell lines not expressing the
FLT3-ITD, namely HL-60 (Figure 2d). We then investigated
whether the reduction in ROS seen upon PKC412 treatment was
due to this downregulation of p22phox by examining the
intracellular localization of the p22phox in MV4-11 cells. We
show that p22phox co-localizes to the ER and its expression
pattern mirrors that of the ROS as seen with PO1 (Figure 2e).
Indeed our data show that approximately 70% of p22phox co-
localizes with KDEL, while approximately 50% of KDEL co-
localizes with p22phox. These data strongly suggest that p22phox
is involved in the ER localized H2O2 production, but for further
confirmation we selectively knocked down p22phox via siRNA.
in 3% PFA/PBS prior to staining with KDEL and P22phox antibodies. Images are represented as a single slice from a Z stack projection. Brightness and
contrast adjustments have been made for convenience, with identical parameters applied across images. Relative measures of co-localization are
included, values are the mean 6 SD and are representative of three independent experiments. Digital images were analyzed with Meta-Morph
software. Scale bar represents 10 mm. (f) Silencing p22phox reduces ROS generation. MV4-11cells were electroporated with either control siRNA or
p22phox siRNA and plated in Poly-D-lysine coated glass bottomed dishes and stained with peroxyorange 1 (PO1), then imaged with a confocal laser
scanning microscope. The same plates were then fixed and stained with the p22phox antibody for immunofluorescence. Brightness and contrast
adjustments have been made for convenience, with identical parameters applied across images. The scale bar represents 10mm.
doi:10.1371/journal.pone.0034050.g002
Figure 3. FLT3-ITD Inhibition results in proteasomal degradation of p22phox. (a) Products of quantitative PCR for p22phox mRNA in
untreated MV4-11 cells (Unt) and cells treated with PKC412 (250nM) for 24 hours were visualised by agarose gel separation, loading control is b-Actin.
Histogram shows relative expression of p22phox mRNA in untreated MV4-11 cells and cells treated with PKC412 (250nM) for 24 hours as determined
by quantitative PCR DDCt-method. Results are expressed as mean 6 SD and are representative of three independent experiments. Statistical analysis
was performed using student t-test (*p,0.005) (b) Western blot analysis of p22phox protein expression in untreated MV4-11 cells (UT), vehicle
controls (Veh), and cells treated with PKC412 (250nM) and lactacystin (5mM; Lac) for 8 hours using b-Actin as a loading control. Histograms represent
the ratio of the intensity of target bands quantified by densitometry factored by the densitometric measurement of loading control band. The data
are expressed as percentage of control, where the ratio in the control was defined as 1. Values are the mean 6 SD and are representative of three
independent experiments (c) Immunoprecipitation of p22phox from whole-cell lysates of untreated MV4-11 cells (Unt), cells treated with PKC412
(250nM) and lactacystin (5 mM; Lac) for 8 hours. Nitrocellulose membranes were probed for the presence of ubiquitin. Values are the mean6 SD and
are representative of three independent experiments.
doi:10.1371/journal.pone.0034050.g003
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Cells in which p22phox was knocked down were then compared to
cells transfected with negative control siRNA, for ROS and
p22phox localization. The knockdown resulted in an almost
complete loss of p22phox protein in the cell and was accompanied
by a dramatic drop in ROS levels in the ER (Figure 2f; Figure S3)
similar to treatment with PKC412. These results indicate that in
MV4-11 cells that endogenous ROS production requires p22phox
and localizes to the ER.
FLT3-ITD Inhibition results in proteasomal degradation of
p22phox
Given that p22phox protein levels are downregulated relatively
rapidly post-treatment with PKC412 (Figure 2a), we investigated
whether this effect was mediated post-transcriptionally. However,
p22phox mRNA levels did not change significantly upon
inhibition of FLT3-ITD up to 24 hours when the protein is
substantially reduced (Figure 3a). Thus, it appeared likely that
p22phox is regulated post-translationally. To test this hypothesis,
we inhibited FLT3-ITD signalling in the presence of lactacystin,
an inhibitor of the proteasome (Figure 3b). By blocking
proteasome function we were able to partially abrogate the
degradation of p22phox after PKC412 treatment. Thus, protea-
somal degradation of p22phox occurs upon inhibition of FLT3
signalling. In order to elucidate how p22phox is targeted to the
proteasome we immunoprecipitated the protein and probed for
ubiqutin moieties as well immunoprecipitating ubiquitinated
proteins and probing for p22phox (Figure 3c; Figure S4). We
found that p22phox ubiquitination increases upon PKC412
treatment, and inhibiting the proteasome causes a build up of
ubiquitinated p22phox in the cell indicating that p22phox is first
ubiquitinated and then degraded by the proteasome. Taken
together these data suggest that regulation via PKC412 was at the
post-translational level.
PKC412-mediated p22phox downregulation requires
GSK3-b activation
Mutated FLT3 signalling is associated with constitutively
activated signalling pathways [32]. Of particular interest is
GSK3-b signalling, given its role in the regulation of proteasomal
degradation in numerous contexts (32–34). GSK3-b is active when
dephosphorylated and thus is likely to be redox regulated. We
show that PKC412 inhibition of FLT3-ITD signalling prevents
phosphorylation of GSK3-b in both MV4-11and MOLM-13 cell
lines (Figure 4a). Given the known role for GSK3-b in proteasomal
regulation we tested whether GSK3-b might be involved in the
downregulation of p22phox seen here. Utilizing either of two
Figure 4. PKC412-mediated p22phox downregulation requires
GSK3-b activation. (a) Western blot analysis of GSK3-b signalling in
untreated MV4-11 and MOLM-13 cells (Unt), vehicle controls (Veh), and
after treatment with PKC412 (250nM) for 16 hours or DPI (5mM) for
1 hour with GAPDH as a loading control (b) Western blot analysis of
p22phox expression in untreated MV4-11 cells (Unt) and upon
treatment with PKC412 (250nM), SB 216763 (10mM; SB), Lithium
Chloride (10mM; LiCl) for 8 hours using b-Actin as a loading control.
Histograms represent the ratio of the intensity of target bands
quantified by densitometry factored by the densitometric measurement
of loading control band. The data are expressed as percentage of
control, where the ratio in the control was defined as 1. Values are the
mean 6 SD and are representative of three independent experiments.
doi:10.1371/journal.pone.0034050.g004
Figure 5. p22phox links FLT3-ITD to STAT5 signalling in AML.
(a) Western blot analysis of signalling pathways in untreated MV4-11
cells (Unt) and 24 hours post knockdown of p22phox protein levels via
siRNA (A, B). Cells were transfected with either of two siRNA oligomers
for p22phox knockdown or a negative control oligomer (Scr) and
compared to untreated cells 24 hours post-transfection. Histograms
represent the ratio of the intensity of target bands quantified by
densitometry factored by the densitometric measurement of loading
control band. The data are expressed as percentage of control, where
the ratio in the control was defined as 1. Values are the mean 6 SD and
are representative of three independent experiments (b) Western blot
analysis of Pim-1 protein expression in untreated MV4-11 cells (Unt),
vehicle controls (Veh) and following treatment with VAS2870 (10mM)
over 4 hours using b-Actin as loading control. Histograms represent the
ratio of the intensity of target bands quantified by densitometry
factored by the densitometric measurement of loading control band.
The data are expressed as percentage of control, where the ratio in the
control was defined as 1. Values are the mean 6 SD and are
representative of three independent experiments.
doi:10.1371/journal.pone.0034050.g005
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known GSK3-b inhibitors, namely lithium chloride and SB
216763, we could almost completely reverse the degradation of
p22phox after treatment with PKC412 (Figure 4b). Inhibiting
AKT with LY 294002 had no effect on p22phox levels after
PKC412 treatment (data not shown). These results indicate that
GSK3-b facilitates the post-translational regulation of p22phox
upon its activation by PKC412 dephosphorylation.
p22phox links FLT3-ITD to STAT5 signalling in AML
It is known that one of the major pathways activated
downstream of FLT3 in AML cells is STAT5, whose constitutive
activation is associated with protection from apoptosis in mutant
FLT3 cells [33]. STAT5 signalling downstream of mutant FLT3
has also been implicated in ROS generation [10]. Growth factor
derived ROS can also mediate phosphorylation of STAT5 in
leukemic cells [17], highlighting the dynamic role ROS can play in
signalling pathways. We examined whether p22phox plays a role
upstream of STAT5 in MV4-11 cells. Knockdown of p22phox
mediated by siRNA gave a reduction in phosphorylation of
STAT5 at 48hours (Figure 5a). Importantly, this was not
accompanied by a reduction in Akt- or ERK-phosphorylation,
which is in agreement with current understanding of FLT3-ITD
signal transduction in AML cell lines [29]. This indicates that the
reduction in phosphorylated-STAT5 was not due to a change in
redox-state of the cells. Interestingly this was accompanied by a
reduction in the levels of the serine/threonine kinase Pim-1, a
target gene of STAT5. Pim-1 has recently been shown as a
downstream effector of signalling by mutated FLT3 on the ER [6]
and is known to regulate critical pathways in AML [20,34]. A
decrease in Pim-1 expression was also seen upon Nox-protein
inhibition by VAS 2870 (Figure 5b) suggesting its regulation upon
p22phox knockdown is through a reduction in Nox-activity also
and is a downstream target of Nox signalling.
Discussion
A number of studies have examined the role of ROS, and
specifically Nox-derived ROS, in leukemia [10,21,29] but to date
an understanding of how ROS contributes to a tumourous
phenotype remains largely unknown. While previously considered
an unwanted by-product of respiration, ROS contribution to
intracellular signalling is now considered to be essential in healthy
as well as tumourous cells. In this work we demonstrated for the
first time that FLT3-ITD drives H2O2 production in the ER and
that this is mediated by the small subunit of the NADPH oxidase,
p22phox. Also, we have shown that p22phox signalling affects
mediators known to be critical for leukemic cell development and
survival.
Nox proteins have been seen localized to the ER in various cell
line types [35,36,37]. However, to date no evidence for Nox-
derived ROS signalling localized to the ER has been presented in
AML. Also, here we show live-cell imaging of localized ROS in
leukemia cells using PO1 fluorescence. While it is difficult to
quantify ROS based on DCF fluorescence [38,39], we show that
H2O2 detected by the highly-specific PO1 dye localizes to the ER.
This dye has been shown to detect endogenous levels of hydrogen
peroxide [40] and here we demonstrate it can be used for co-
localization studies, showing that ROS generated in MV4-11 cells
co-localise with ER tracker dyes. Thus, the H2O2 generated
downstream of FLT3 appears to be H2O2, the highest concen-
tration of which is in the ER. Recently, it was shown that Nox-
derived ROS induced by oxidized low-density lipoprotein
(OxLDL) in monocyte-derived macrophages localized to the ER
[41]. Our localization of H2O2to the ER is similar to that of Lee
et al., in an analogous system of suspension myeloid cells [41]. The
ROS generation we see is almost completely inhibitable by both
PKC412 and DPI, indicating that it is both FLT3- and Nox-
dependent (Figure 1). Signalling downstream of the FLT3-ITD
results in a number of pathway outcomes, and of particular
interest is the activation of STAT5 at the ER [6,30]. This
compartmentalization of signalling processes downstream of
FLT3-ITD correlates with the ROS localization we have shown
here. Nox proteins are generally membrane-bound and although
there is evidence for Nox localization throughout the cell these
results are nonetheless surprising by suggesting that the Nox
complex in AML generates significant amounts of ROS at the ER.
Some evidence suggests that Nox proteins assemble with p22phox
at the ER prior to the mature heterodimer complex trafficking to
the plasma membrane [42], however in our system ROS are
generated at the ER.
Nox family members have been associated with numerous
signalling pathways relevant to survival, apoptosis, migration and
transformation in AML cells [43] all of which make them excellent
candidates for study. Here we have shown that inhibition of FLT3-
ITD signalling results in the downregulation of p22phox
(Figure 2a) without affecting the expression of other Nox proteins.
p22phox was first identified as the small membrane-associated
subunit of flavocytochrome b558 [44] and has since been identified
as as a component of Nox1-4 [45]. Full functioning of these Nox
Figure 6. Schematic of Proposed Mechanism for p22phox-
mediated H2O2 signalling in FLT3-ITD AML cell lines. p22phox is
required for the production of H2O2 in AML cell lines at the Endoplasmic
reticulum. Inhibition of FLT3 signalling in these cells leads to
degradation of p22phox by the proteasome, which requires active
GSK3-b. Removal of p22phox from this system halts STAT5 signalling to
Pim-1.
doi:10.1371/journal.pone.0034050.g006
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proteins require p22phox [46,47,48]. Thus, the complete loss of
p22phox in the cell is likely to have significant effects on any ROS
regulated pathways. Also, recent evidence shows that p22phox
localizes with Nox4 in the ER in human monocyte-derived
macrophages [41] suggesting that loss of p22phox at the ER in our
system could regulate ROS derived from Nox4. Here we show for
the first time that p22phox can be found in the ER in AML cell
lines and indeed appears to be required for the high levels of ROS
found there (Figure 2e). Therefore, it appears that inhibition of
FLT3 signalling leads to a downregulation of p22phox and this in
turn drives down the level of ROS in the cell dramatically.
Given that the levels of p22phox drop relatively soon after
FLT3 inhibition, the question was raised as to how this was
mediated. We have shown that the level of mRNA is unaffected by
PKC412 and that proteasomal inhibition prevents protein
degradation after ubiquitination. To our knowledge, treatment
with PKC412 has not been reported to induce the proteasomal
degradation of any proteins in AML cells and that this occurs to
p22phox is a significant finding. Confirming that this was not a
general stress response due to removal of FLT3 signalling we have
seen that chaperone proteins Hsp70 and Hsp90, as well as a
marker of the unfolded-stress response Grp78, are all unaffected
by PKC412 treatment (data not shown). Interestingly, it is known
that the von Hippel-Lindau tumor suppressor gene (VHL) is
responsible for downregulating p22phox in renal carcinoma cells
via ubiquitination and subsequent proteasomal degradation [49].
Thus, p22phox is downregulated by the tumour suppressor gene
VHL and by inactivation of the oncogene FLT3. This raises the
intriguing possibility that p22phox plays a role linking oncogenesis
and downstream effectors in a more general context and that it is
not simply involved in these particular disease models.
Inhibition of FLT3 signalling was associated with an increase in
activated GSK3-b, through a reduction in its deactivated
phosphorylated-form. We have demonstrated that this activation
of GSK3-b is essential for the reduction of p22phox levels
(Figure 4). Inhibition of GSK3-b completely abrogates p22phox
protein degradation, which demonstrates that without GSK3-b
signalling p22phox cannot be processed by the proteasome.
GSK3-b is known to target proteins to the proteasome with P21,
Cyclin D3 and HIF-1a, for example, all processed in this manner
[50,51,52]. While it is known that p22phox can be processed to
the proteasome via ubiquitination, a role for GSK3-b in this
process has not been previously demonstrated. However, it
remains unclear how GSK3-b mediates its effect on p22phox
and there may be other signalling intermediates involved.
The dramatic reduction in p22phox and ROS upon PKC412
treatment would likely have consequences for downstream
signalling relevant to AML. Indeed, targeted knockdown of
p22phox resulted in a large reduction in the active, phosphory-
lated STAT5 and one of its target genes Pim-1 (Figure 5). Both
STAT5 and Pim-1 are known to be extremely important in AML
development and progression [34]. This result indicates a novel
role for p22phox in regulating signalling cascades vital to AML
progression at the level of the transcriptional activator STAT5.
Pim-1 has recently been shown as a downstream effector of
aberrant signalling by mutated FLT3 on the ER [53] and is known
to regulate critical pathways in AML [20,34]. We propose a
mechanism for the function of p22phox in the mediation of
STAT5 signalling in AML in Figure 6, based on our data
presented here. p22phox plays a role in maintaining essential
signalling pathways in AML and it achieves this through
facilitating the production of ROS. Interfering with endogenous
ROS levels here by knocking down p22phox is enough to stop
STAT5 signalling. Given the importance of STAT5 in AML this
highlights the importance of the redox state of the cell in AML,
and tumours in general. Also it is worth noting that targeting of
p22phox may be of therapeutic benefit given that our data show it
to be upstream of these pathways.
Supporting Information
Figure S1 H2O2 reduction in MV4-11 AML cells upon
FLT-3 and Nox-inhibition. Densitometry analysis of data
represented in Figure 1. Digital images were analyzed with Meta-
Morph software. Bar chart represents mean 6 SE and are
representative of three independent experiments.
(TIF)
Figure S2 Mitochondrial ROS levels are unaffected by
FLT3-inhibition in MV4-11 AML cells. Densitometry
analysis of data represented in Figure 1. Digital images were
analyzed with Meta-Morph software. Bar chart represents mean
6 SE and are representative of three independent experiments.
(TIF)
Figure S3 siRNA mediated reduction of p22phox in
MV4-11 AML cells. Densitometry analysis of data represented
in Figure 2. Digital images were analyzed with Meta-Morph
software. Bar chart represents mean 6 SE and are representative
of three independent experiments.
(TIF)
Figure S4 Ubiquitination of p22phox upon FLT3-inhibi-
tion in MV4-11 AML cells. Immunoprecipitation of ubiquiti-
nated proteins from whole-cell lysates of untreated MV4-11 cells
(Unt) and cells treated with PKC412 (250nM) for 8 hours.
Nitrocellulose membranes were probed for the presence of
p22phox. Values are the mean 6 SD and are representative of
three independent experiments.
(TIF)
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